Trump Administration Sinks Teeth Into Paring Down Drug Prices, On 5 Key Points
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
The independent source for health policy research, polling, and news.
401 - 420 of 465 Results
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
Inspector general identifies possible problems in nearly 23 percent of pharmacies that bill Medicare for blended creams, gels and lotions.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Alice Ollstein of Talking Points Memo and Kimberly Leonard of the Washington Examiner talk about the new push on health legislation by Republicans in the House, as well as developments on Medicaid work requirements, drug prices and the fate of children separated from their parents at the U.S.-Mexican border. Plus, for extra credit, the panelists offer their favorite health stories of the week.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
Vaping is becoming increasingly popular in the United States, especially among young people. This fact is triggering an unexpected divide within the public health community and complicating efforts to regulate the industry.
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Restaurants, convenience stores, vending machines and pizza delivery services are among the businesses that will have to provide calories counts to consumers.
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
The ‘scary’ findings show a discouraging lack of progress in cleaning the devices, despite more vigorous efforts in the wake of deadly superbug outbreaks, experts say.
California and federal officials have cracked down on a major compounding pharmacy they say posed a threat to public safety, but their actions are worsening shortages of medications that doctors rely on to keep their patients out of pain.
Suffering Americans seek medical marijuana as an alternative to opioids and other powerful pharmaceuticals. Though legal in 29 states, some doctors say the lack of strong data makes it hard to recommend.
Kaiser Health News reporter Sarah Jane Tribble sat down with Food and Drug Administration Commissioner Scott Gottlieb on C-SPAN’s "Newsmakers" program. The conversation ranged from how the nation should combat the opioid epidemic to reining in drug prices.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Margot Sanger-Katz of The New York Times discuss the apparent demise of bipartisan legislation aimed at shoring up parts of the Affordable Care Act. They also discuss aggressive new efforts by the Food and Drug Administration to regulate tobacco products. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
In a historic move, the Food and Drug Administration stated its intent Thursday to require tobacco companies to cut nicotine levels in their products to make them less addictive. Stripping cigarettes of addictive power could lead an estimated 5 million adults to quit smoking within a year of the plan.
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
For some federal health programs, a shuttered government means business as usual. But the congressional impasse over funding will hit others hard.
The Republican senator sent out letters to the Food and Drug Administration and HHS demanding an explanation about a rogue herpes vaccine trial.
© 2026 KFF